The content on this site is intended for healthcare professionals only
Dr Matteo Lambertini meets with ecancer at SABCS 2017 to discuss the safety and effects on fertility of temporary ovarian suppression during breast cancer treatment with gonadotrophin releasing hormone (GnRH) analogues.
Looking at data from 5 European trials, Dr Lambertini outlines the safety and lasting fertility of the total patient populations, half of whom received GRH alongside their cancer treatments.
With improved fertility and ovarian function, as well as equal safety and overall survival scores, Dr Lambertini recommends this as a treatment option for all young breast cancer patients concerned with their later ovarian function.
Watch the press conference for more.
Transforming cancer care in India: The Access Cancer Care Initiative
The added value of integrative medicine
Insights into germline genetic screening of breast cancer patients
ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies
Psychological issues in familial cancer
Multiple myeloma In Rwanda: The need for further research
GIST tumours and soft tissue sarcomas
Clinical behaviour of breast cancer in young BRCA carriers and prognostic impact of the timing of genetic testing
Genomic testing: Awareness and effective communication between healthcare professionals and patients
